



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/868,884	02/05/2002	Andrew Baxter	06275-233001	7953
26164	7590	11/02/2006	EXAMINER	
FISH & RICHARDSON P.C. P.O BOX 1022 MINNEAPOLIS, MN 55440-1022			TRUONG, TAMTHOM NGO	
		ART UNIT	PAPER NUMBER	
		1624		

DATE MAILED: 11/02/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

TK

Office Action Summary	Application No.	Applicant(s)	
	09/868,884	BAXTER ET AL.	

Examiner	Art Unit	
Tamthom N. Truong	1624	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 10-24-06 (RCE).

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-3,6-11,21,26-28 and 30-33 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1-3,6-11,21,26-28 and 30-33 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____.

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. attached.

5) Notice of Informal Patent Application

6) Other: _____.

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114.

Applicant's submission filed on 10-12-06 has been entered.

Claims 4, 5, 12-20, 22-25 and 29 have been cancelled.

Claims 1-3, 6-11, 21, 26-28 and 30-33 are pending.

A telephone interview was conducted with Ms. Catherine McCarty on 10-24-06 to suggest the deletion of "solvates" which does not have adequate support in the specification. However, Ms. McCarty has not responded to said suggestion.

Claim Rejections - 35 USC § 112, First Paragraph

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

2. **Scope of Enablement:** Claims 1-3, 6-11, 21, 26-28 and 30-33 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for making and using

compounds, isomers, racemates, tautomers and pharmaceutical salts of formula I, does not reasonably provide enablement for making and using solvates of formula I. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

The following factors have been considered in the determination of an enabling disclosure:

- (1) The breadth of the claims;
- (2) The amount of direction or guidance presented;
- (3) The state of the prior art;
- (4) The relative skill of those in the art;
- (5) The predictability or unpredictability of the art;
- (6) The quantity of experimentation necessary;

[See *Ex parte Forman*, 230 USPQ 546 (Bd. Pat. App. & Int., 1986); also *In re Wands*, 858 F. 2d 731, 8 USPQ 2d 1400 (Fed. Cir. 1988)].

The breadth of the claims:

The above claims recite “solvates” of compounds formula (I). The term “solvates” covers various forms of the same compound at different proportions of solvents. Thus, the scope of said claims is unduly broad.

The amount of direction or guidance presented:

Although the specification briefly defines what “solvates” are, it does not provide working examples to guide the skilled chemist to select a solvate. There is no guidance on what

proportion of solvent to use for obtaining a “solvate”. Thus, the specification fails to provide sufficient enablement for making “solvates” of the claimed compounds.

The state of the prior art:

Although it is not unusual to expect a “solvate” of a compound, the process for selecting a particular solvent to make a solvate is not standard for all drugs. For the claimed compound, there is no reference teaching any possible solvate. Thus, the state of the prior art does not support the broad scope of the above claims.

The relative skill of those in the art:

Even with the advanced training, the skilled clinician would have to engage in extensive research to select a particular “solvate” for each compound from the large Markush group of formula I. Not only one has to determine an IC_{50} value, but also *in-vivo* activity to establish an LD_{50} , therapeutic index. Given a large Markush group of formula I, such a task would require a tremendous amount of effort, time and resource.

The predictability or unpredictability of the art & The quantity of experimentation necessary:

The process of making a “solvate” is quite unpredictable because it is not possible to predict whether solid solutions will form and at what stoichiometry proportion (i.e, one, two, or half a molecule of solvent added per molecule of host).

Thus, with such a limited teaching from the specification and the art, the skilled chemist would have to engage in undue experimentation to make the hundreds of thousands of compounds covered by “solvates” of compounds of formula I recited in the above claims.

Claim Rejections - 35 USC § 112, Second Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

3. Claims 1-3, 6-11, 21, 26-28 and 30-33 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 1 recites the limitation of "and optical isomers, racemates, and tautomers thereof and pharmaceutically acceptable salts..." which seems to suggest a mixture. It is suggested that the word 'and' be replaced with 'or'.

References cited on PTO-892

References cited on PTO-892 show state of the art. While they disclose thiophene compounds substituted with an amide and urea groups, their effective filing dates do not antedate the effective filing date of this application.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 571-272-0676. The examiner can normally be reached on M, T and Th (9:00-5:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1624

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Tamthom N. Truong
Tamthom N. Truong
Examiner
Art Unit 1624

10-27-06

James O. Wilson
JAMES O. WILSON
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600